IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$72.37 USD
+0.37 (0.51%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $72.30 -0.07 (-0.10%) 5:02 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Intra-Cellular Therapies (ITCI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$88.73 | $120.00 | $65.00 | 23.24% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Intra-Cellular Therapies comes to $88.73. The forecasts range from a low of $65.00 to a high of $120.00. The average price target represents an increase of 23.24% from the last closing price of $72.00.
Analyst Price Targets (15)
Broker Rating
Intra-Cellular Therapies currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 15 recommendations.
Of the 14 recommendations deriving the current ABR, 10 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 73.33%, while Buy represented 13.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 11 | 11 | 11 | 11 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.40 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
4/5/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
2/23/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
2/16/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
12/14/2023 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
11/2/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 14 |
Average Target Price | $88.73 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.33 |